Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi Win the 2025 Nobel Prize in Medicine for Discoveries on Immune Regulation
A Landmark Discovery in Immune Tolerance
The 2025 Nobel Prize in Physiology or Medicine has been awarded jointly to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their groundbreaking discoveries revealing how the human immune system maintains internal balance. Their pioneering work on regulatory T-cells shed light on the complex mechanism of peripheral immune tolerance, offering crucial insights into how the immune system distinguishes between harmful pathogens and the body’s own tissues.
The Nobel Assembly at the Karolinska Institute announced the prize from Stockholm this morning, calling their findings “a cornerstone of modern immunology.” These discoveries have not only transformed the scientific understanding of self-tolerance but have also opened new paths for treating and potentially curing autoimmune diseases such as type 1 diabetes, lupus, multiple sclerosis, and rheumatoid arthritis.
The recognition underscores decades of research that bridged fundamental biology and clinical medicine, illustrating how molecular insights can be translated into therapeutic advances.
The Science Behind the Award
At the heart of this year’s Nobel Prize is the concept of immune regulation—the body’s capacity to defend against external threats while avoiding harmful reactions to its own cells. In a properly functioning immune system, the body’s defense mechanisms recognize self-antigens and restrain attacks on them. When that balance breaks down, it results in autoimmune disorders, in which the immune system targets the body’s organs and tissues.
In the late 1980s, Japanese immunologist Shimon Sakaguchi identified a small population of immune cells that played a critical role in maintaining this delicate balance. These cells, later known as regulatory T-cells (Tregs), express a molecule called Foxp3, which is vital for their development and function. Without Foxp3, Tregs cannot perform their protective role, leading to uncontrolled immune activity.
American scientists Mary E. Brunkow and Fred Ramsdell later discovered that mutations in the Foxp3 gene were responsible for severe autoimmune disorders in both humans and mice. Their work established the genetic and mechanistic foundation of immune tolerance, cementing Tregs’ role as central guardians of immune homeostasis.
The collective research of these three scientists provided the first comprehensive picture of how the immune system self-regulates, fundamentally changing immunological theory and enabling therapeutic innovation.
From Discovery to Medical Application
The discovery of regulatory T-cells has moved well beyond the laboratory setting. Today, this research underpins multiple clinical trials exploring the potential of Treg-based therapy to treat autoimmune conditions. The use of Treg cell infusions aims to restore immune balance without the broad immune suppression caused by traditional medications such as corticosteroids or biologics.
In recent years, early-stage clinical trials have shown encouraging results in patients with type 1 diabetes and graft-versus-host disease, where donor immune cells attack the recipient’s tissues after bone marrow transplantation. By expanding and reintroducing a patient’s own Tregs, researchers have observed a reduction in immune attacks and a stabilization of disease progression.
Pharmaceutical companies and biotech startups across North America, Europe, and Asia have invested heavily in Treg research and therapy development. Experts estimate that the global market for autoimmune therapies could exceed $150 billion annually by 2030, driven in part by new treatments rooted in discoveries like those of Brunkow, Ramsdell, and Sakaguchi.
Historical Context: A Century of Immune Insight
This year’s Nobel Prize joins a long lineage of discoveries shaping the understanding of the immune system. Earlier milestones include the identification of antibodies in the early 1900s, the discovery of the major histocompatibility complex (MHC) in the 1950s, and the elucidation of how T-cells recognize antigens in the 1980s—advances that have each led to their own Nobel recognitions.
However, while earlier work explained how the immune system activates to attack invaders, the research honored in 2025 focuses on the equally vital process of immune restraint. Sakaguchi’s early experiments demonstrated that without regulatory T-cells, immune responses could spiral out of control, leading to systemic autoimmune damage. Subsequent studies by Brunkow and Ramsdell provided the genetic evidence that explained how such dysregulation occurs in both animal models and human patients.
Historians of medicine describe the trio’s discoveries as completing the circle of immunology—first understanding how the immune system defends, then how it prevents self-destruction.
Global Significance and Regional Reactions
The announcement has sparked celebration across the international scientific community. Colleagues praised the laureates’ persistence and cooperation across borders, noting that their research exemplified how collaboration between U.S. and Japanese scientists can accelerate major biomedical breakthroughs.
At the University of Kyoto, where Sakaguchi has led immunology research for decades, students and faculty gathered to watch the Nobel livestream, erupting into cheers at the announcement. In Seattle, where Brunkow and Ramsdell conducted their pivotal genetic studies at the biotech firm Immunex (now part of Amgen), former colleagues described the award as “long overdue recognition for transformative science.”
Across Asia, Europe, and North America, immunologists drew parallels between this discovery and the wider race to harness immune cells for therapy. While CAR-T cell therapy—which engineers immune cells to attack cancers—has dominated oncology in recent years, Treg-based therapy represents the mirror image: teaching immune cells when not to attack.
Economic and Therapeutic Impact
The potential therapeutic impact of this discovery extends across multiple industries, including biotechnology, pharmaceuticals, and healthcare systems worldwide. The ability to selectively modulate immune activity could revolutionize treatment approaches for chronic illnesses, which are among the leading causes of disability and healthcare spending globally.
Biotech companies are now exploring gene-editing technologies, such as CRISPR, to enhance the stability and function of Tregs before infusion into patients. Meanwhile, hospitals and research centers are investing in Treg expansion facilities to prepare for a new generation of cell-based immune therapies. Analysts project that if Treg therapies achieve regulatory approval within the next five to seven years, they could reshape the landscape of immunological medicine much as monoclonal antibodies did in the late 20th century.
The economic ripple effects are also expected to touch research funding priorities. National science foundations and industry partners may redirect resources toward immune regulation, further stimulating innovation in this emerging field.
The Human Impact and Promise for the Future
For millions living with autoimmune diseases, this Nobel-winning discovery represents more than a scientific achievement—it symbolizes hope. Autoimmune disorders affect roughly 5–10% of the world’s population, with many conditions currently non-curable and managed only through lifelong immunosuppressive drugs.
The idea that these diseases might one day be treated by restoring natural immune balance, rather than bluntly suppressing immune activity, signals a profound shift in medicine. Patients could benefit from safer, longer-lasting therapies that restore normal immune function rather than merely controlling symptoms.
While challenges remain—such as ensuring the long-term stability of infused Treg cells and identifying which patients may benefit most—the scientific community views this field as one of the most promising frontiers in biomedical science.
Laureates Reflect on a Lifetime of Discovery
In interviews following the announcement, the laureates expressed gratitude and humility. Sakaguchi called the award “a tribute to decades of curiosity about how the body maintains peace within itself.” Ramsdell highlighted the teamwork behind their success, emphasizing that “scientific progress often depends on connecting many threads across laboratories, institutions, and continents.” Brunkow, describing her reaction as “astonishment and joy,” dedicated the award to young scientists pursuing curiosity-driven research.
Their words echo the Nobel Assembly’s statement emphasizing that this discovery exemplifies the essence of scientific inquiry—persistent observation, collaboration, and a willingness to explore the unknown.
Looking Ahead: The Next Era of Immune Medicine
The 2025 Nobel Prize in Medicine marks not only a recognition of past discoveries but also a glimpse into the future of immunology. As ongoing research continues to refine Treg-based therapies, scientists anticipate an expanding frontier of precision immunotherapy, merging genetics, cell biology, and biotechnology in unprecedented ways.
This award spotlights a scientific legacy built on patience, rigor, and interdisciplinary collaboration. As the world continues to face challenges from chronic disease to emerging infections, understanding how to control the immune system’s remarkable power may prove to be one of humanity’s most vital accomplishments.
With this year’s honor, Brunkow, Ramsdell, and Sakaguchi join the ranks of Nobel laureates whose discoveries have reshaped modern medicine—offering both scientific insight and renewed hope for health and healing in the years ahead.